Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?

1 D. Tomasoni, M. Adamo M, C.M. Lombardi, M. Metra, “Highlights in heart failure”, ESC Heart Fail, vol. 6 no. 6, pp. 1105–1127, Dec 2019. doi: 10.1002/ehf2.12555 PMID: 31997538 PMCID: PMC6989277 TomasoniD. Adamo MM. LombardiC.M. MetraM. “Highlights in heart failure” ESC Heart Fail 6 6 1105 1127 Dec 2019 10.1002/ehf2.12555 PMID: 31997538 PMCID: PMC6989277 698927731997538 Open DOISearch in Google Scholar

2 D. Tomasoni, M. Adamo, M.S. Anker, S. von Haehling, A.J.S. Coats, M. Metra, “Heart failure in the last year: progress and perspective”, ESC Heart Fail, vol. 7 no. 6, pp. 3505–3530, 2020. doi: 10.1002/ehf2.13124 PMID: 33277825 PMCID: PMC7754751 TomasoniD. AdamoM. AnkerM.S. von HaehlingS. CoatsA.J.S. MetraM. “Heart failure in the last year: progress and perspective” ESC Heart Fail 7 6 3505 3530 2020 10.1002/ehf2.13124 PMID: 33277825 PMCID: PMC7754751 775475133277825 Open DOISearch in Google Scholar

3 L. Stretti, D. Zippo, A.J.S. Coats, M.S. Anker, S. von Haehling, M. Metra, D. Tomasoni “A year in heart failure: an update of recent findings”, ESC Heart Fail, vol. 8 no. 6, pp. 4370–4393, December 2021. doi: 10.1002/ehf2.13760 PMID: 34918477 PMCID: PMC9073717 StrettiL. ZippoD. CoatsA.J.S. AnkerM.S. von HaehlingS. MetraM. TomasoniD. “A year in heart failure: an update of recent findings” ESC Heart Fail 8 6 4370 4393 December 2021 10.1002/ehf2.13760 PMID: 34918477 PMCID: PMC9073717 907371734918477 Open DOISearch in Google Scholar

4 T.A. McDonagh, M. Metra, M.Adamo, R.S. Gardner, A. Baumbach, M. Böhm, H. Burri, J. Butler, J. Čelutkienė, O. Chioncel, et al., “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC”, Eur. Heart J., 42, pp. 3599–3726, 2021. McDonaghT.A. MetraM. AdamoM. GardnerR.S. BaumbachA. BöhmM. BurriH. ButlerJ. ČelutkienėJ. ChioncelO. “2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC” Eur. Heart J. 42 3599 3726 2021 10.1016/j.rec.2022.05.00535636830 Search in Google Scholar

5 A.N. Emara, N.O. Mansour, M.H. Elnaem, M. Wadie, I.S. Dehele, M.E.E. Shams, “Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials”, J Clin Med., vol. 11 no. 11, p. 3112, May 2022. doi: 10.3390/jcm11113112 PMID: 35683505 PMCID: PMC9181246 EmaraA.N. MansourN.O. ElnaemM.H. WadieM. DeheleI.S. ShamsM.E.E. “Efficacy of Nondiuretic Pharmacotherapy for Improving the Treatment of Congestion in Patients with Acute Heart Failure: A Systematic Review of Randomised Controlled Trials” J Clin Med. 11 11 3112 May 2022 10.3390/jcm11113112 PMID: 35683505 PMCID: PMC9181246 918124635683505 Open DOISearch in Google Scholar

6 A. Cahn, O. Mosenzon, S.D. Wiviott, A. Rozenberg, I. Yanuv, E.L. Goodrich, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, I.A.M. Gause-Nilsson, M. Fredriksson, P.A. Johansson, A.M. Langkilde, M.S. Sabatine, I. Raz, “Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study”, Diabetes Care, vol. 43 no. 2, pp. 468–475, December 2019. doi: 10.2337/dc19-1476. Epub 2019 Dec 16. PMID: 31843945. CahnA. MosenzonO. WiviottS.D. RozenbergA. YanuvI. GoodrichE.L. MurphyS.A. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. Gause-NilssonI.A.M. FredrikssonM. JohanssonP.A. LangkildeA.M. SabatineM.S. RazI. “Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study” Diabetes Care 43 2 468 475 December 2019 10.2337/dc19-1476 Epub 2019 Dec 16. PMID: 31843945. 31843945 Open DOISearch in Google Scholar

7 L.M. Pérez-Belmonte, J. Sanz-Cánovas, M. Millán-Gómez, J. Osuna-Sánchez, A. López-Sampalo, M. Ricci, M. Jiménez-Navarro, M.D. López-Carmona, M.R. Bernal-López, M.A. Barbancho, J.P. Lara, R. Gómez-Huelgas, “Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure”, J Am Geriatr Soc., vol. 70 no. 3, pp. 862–871, November 2021. doi: 10.1111/jgs.17585 PMID: 34843628 Pérez-BelmonteL.M. Sanz-CánovasJ. Millán-GómezM. Osuna-SánchezJ. López-SampaloA. RicciM. Jiménez-NavarroM. López-CarmonaM.D. Bernal-LópezM.R. BarbanchoM.A. LaraJ.P. Gómez-HuelgasR. “Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure” J Am Geriatr Soc. 70 3 862 871 November 2021 10.1111/jgs.17585 PMID: 34843628 34843628 Open DOISearch in Google Scholar

8 F. Ilyas, L. Jones, S.L. Tee, M. Horsfall, A. Swan, F. Wollaston, T. Hecker, C. De Pasquale, S. Thomas, W. Chong, S. Stranks, A.A. Mangoni, J.B. Selvanayagam, D.P. Chew, C.G. De Pasquale. “Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial”, ESC Heart Fail., vol. 8 no. 5, pp. 4346–4352, August 2021. doi: 10.1002/ehf2.13553 PMID: 34382353 PMCID: PMC8497349 IlyasF. JonesL. TeeS.L. HorsfallM. SwanA. WollastonF. HeckerT. De PasqualeC. ThomasS. ChongW. StranksS. MangoniA.A. SelvanayagamJ.B. ChewD.P. De PasqualeC.G. “Acute pleiotropic effects of dapagliflozin in type 2 diabetic patients with heart failure with reduced ejection fraction: a crossover trial” ESC Heart Fail. 8 5 4346 4352 August 2021 10.1002/ehf2.13553 PMID: 34382353 PMCID: PMC8497349 849734934382353 Open DOISearch in Google Scholar

9 D. Kolijn, S, Pabel, Y. Tian, M. Lódi, M. Herwig, A. Carrizzo, S. Zhazykbayeva, Á. Kovács, G.Á. Fülöp, I. Falcão-Pires, P.H. Reusch, S.V. Linthout, Z. Papp, L. van Heerebeek, C. Vecchione, L.S. Maier, M. Ciccarelli, C. Tschöpe, A. Mügge, Z. Bagi, S. Sossalla, N. Hamdani, “Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation”, Cardiovasc Res., vol. 117 no. 2, pp. 495–507, January 2021. doi: 10.1093/cvr/cvaa123 PMID: 32396609 KolijnD. PabelS TianY. LódiM. HerwigM. CarrizzoA. ZhazykbayevaS. KovácsÁ. FülöpG.Á. Falcão-PiresI. ReuschP.H. LinthoutS.V. PappZ. van HeerebeekL. VecchioneC. MaierL.S. CiccarelliM. TschöpeC. MüggeA. BagiZ. SossallaS. HamdaniN. “Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation” Cardiovasc Res. 117 2 495 507 January 2021 10.1093/cvr/cvaa123 PMID: 32396609 32396609 Open DOISearch in Google Scholar

10 T. Koufakis, O.G. Mustafa, R.A. Ajjan, X. Garcia-Moll, P. Zebekakis, G. Dimitriadis, K. Kotsa, “From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients”, Drugs, vol. 82 no. 9 pp. 949–955, June 2022. doi: 10.1007/s40265-022-01730-2 PMID: 35678922 PMCID: PMC9178534 KoufakisT. MustafaO.G. AjjanR.A. Garcia-MollX. ZebekakisP. DimitriadisG. KotsaK. “From Skepticism to Hope: The Evolving Concept of the Initiation and Use of Sodium-Glucose Cotransporter 2 Inhibitors in Hospitalized Patients” Drugs 82 9 949 955 June 2022 10.1007/s40265-022-01730-2 PMID: 35678922 PMCID: PMC9178534 917853435678922 Open DOISearch in Google Scholar

11 A. Groenewegen, F.H. Rutten, “Sodium-glucose co-transporter 2 inhibitors and acute heart failure”, Eur J Heart Fail, vol. 2 no. 4, pp. 723–725, April 2020. doi: 10.1002/ejhf.1759 PMID: 32072715 GroenewegenA. RuttenF.H. “Sodium-glucose co-transporter 2 inhibitors and acute heart failure” Eur J Heart Fail 2 4 723 725 April 2020 10.1002/ejhf.1759 PMID: 32072715 32072715 Open DOISearch in Google Scholar

12 K. Thiele, M. Rau, N.K. Hartmann, M. Möller, J. Möllmann, J. Jankowski, A.P. Keszei, M. Böhm, J. Floege, N. Marx, M. Lehrke, “Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure”, ESC Heart Fail, vol. 9 no. 4, pp. 2233–2238, May 2022. doi: 10.1002/ehf2.13955. PMID: 35611683 PMCID: PMC9288802 ThieleK. RauM. HartmannN.K. MöllerM. MöllmannJ. JankowskiJ. KeszeiA.P. BöhmM. FloegeJ. MarxN. LehrkeM. “Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure” ESC Heart Fail 9 4 2233 2238 May 2022 10.1002/ehf2.13955 PMID: 35611683 PMCID: PMC9288802 928880235611683 Open DOISearch in Google Scholar

13 V. Rotbain Curovic, M.B. Houlind, T.W. Hansen, J. Eugen-Olsen, J.C. Laursen, M.K. Eickhoff, F. Persson, P. Rossing, “Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor”, Front Pharmacol, 27, 13, 799915, April 2022. doi: 10.3389/fphar.2022.799915 PMID: 35571091 PMCID: PMC9091812 Rotbain CurovicV. HoulindM.B. HansenT.W. Eugen-OlsenJ. LaursenJ.C. EickhoffM.K. PerssonF. RossingP. “Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor” Front Pharmacol 27 13 799915 April 2022 10.3389/fphar.2022.799915 PMID: 35571091 PMCID: PMC9091812 909181235571091 Open DOISearch in Google Scholar

14 G. Savarese, N. Sattar, J. Januzzi, S. Verma, L.H. Lund, D. Fitchett, C. Zeller, J.T. George, M. Brueckmann, A.P. Ofstad, S.E. Inzucchi, C. Wanner, B. Zinman, J. Butler, “Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality”, Circulation, vol. 139, no. 11, pp. 1458–1460, March 2019. doi: 10.1161/CIRCULATIONAHA.118.038339 PMID: 30855996 SavareseG. SattarN. JanuzziJ. VermaS. LundL.H. FitchettD. ZellerC. GeorgeJ.T. BrueckmannM. OfstadA.P. InzucchiS.E. WannerC. ZinmanB. ButlerJ. “Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality” Circulation 139 11 1458 1460 March 2019 10.1161/CIRCULATIONAHA.118.038339 PMID: 30855996 30855996 Open DOISearch in Google Scholar

15 D.L. Bhatt, M. Szarek, P.G. Steg, C.P. Cannon, L.A. Leiter, D.K. McGuire, J.B. Lewis, M.C. Riddle, A.A. Voors, M. Metra, L.H. Lund, M. Komajda, J.M. Testani, C.S. Wilcox, P. Ponikowski, R.D. Lopes, S. Verma, P. Lapuerta, B. Pitt, “SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure”, N Engl J Med, vol. 384 no. 2, pp.117–128, Jan 2021. doi: 10.1056/NEJMoa2030183 PMID: 33200892 BhattD.L. SzarekM. StegP.G. CannonC.P. LeiterL.A. McGuireD.K. LewisJ.B. RiddleM.C. VoorsA.A. MetraM. LundL.H. KomajdaM. TestaniJ.M. WilcoxC.S. PonikowskiP. LopesR.D. VermaS. LapuertaP. PittB. “SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” N Engl J Med 384 2 117 128 Jan 2021 10.1056/NEJMoa2030183 PMID: 33200892 33200892 Open DOISearch in Google Scholar

16 A.A. Voors, C.E. Angermann, J.R. Teerlink, S.P. Collins, M. Kosiborod, J. Biegus, J.P. Ferreira, M.E. Nassif, M.A. Psotka, J. Tromp, C.J.W. Borleffs, C. Ma, J. Comin-Colet, M. Fu, S.P. Janssens, R.G. Kiss, R.J. Mentz, Y. Sakata, H. Schirmer, M. Schou, P.C. Schulze, L. Spinarova, M. Volterrani, J.K. Wranicz, U. Zeymer, S. Zieroth, M. Brueckmann, J.P. Blatchford, A. Salsali, P. Ponikowski, “The SGLT₂ inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial”, Nat Med, vol. 28 no. 3, pp. 568–574, February 2022. doi: 10.1038/s41591-021-01659-1 PMID: 35228754 PMCID: PMC8938265 VoorsA.A. AngermannC.E. TeerlinkJ.R. CollinsS.P. KosiborodM. BiegusJ. FerreiraJ.P. NassifM.E. PsotkaM.A. TrompJ. BorleffsC.J.W. MaC. Comin-ColetJ. FuM. JanssensS.P. KissR.G. MentzR.J. SakataY. SchirmerH. SchouM. SchulzeP.C. SpinarovaL. VolterraniM. WraniczJ.K. ZeymerU. ZierothS. BrueckmannM. BlatchfordJ.P. SalsaliA. PonikowskiP. “The SGLT₂ inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial” Nat Med 28 3 568 574 February 2022 10.1038/s41591-021-01659-1 PMID: 35228754 PMCID: PMC8938265 893826535228754 Open DOISearch in Google Scholar

17 M.N. Kosiborod, C.E. Angermann, S.P. Collins, J.R. Teerlink, P. Ponikowski, J. Biegus, J. Comin-Colet, J.P. Ferreira, R.J. Mentz, M.E. Nassif, M.A. Psotka, J. Tromp, M. Brueckmann, J.P. Blatchford, A. Salsali, A.A. Voors, “Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial”, vol. 146 no. 4, pp. 279–288, April 2022. doi: 10.1161/CIRCULATIONAHA.122.059725 PMID: 35377706 PMCID: PMC9311476 KosiborodM.N. AngermannC.E. CollinsS.P. TeerlinkJ.R. PonikowskiP. BiegusJ. Comin-ColetJ. FerreiraJ.P. MentzR.J. NassifM.E. PsotkaM.A. TrompJ. BrueckmannM. BlatchfordJ.P. SalsaliA. VoorsA.A. “Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial” 146 4 279 288 April 2022 10.1161/CIRCULATIONAHA.122.059725 PMID: 35377706 PMCID: PMC9311476 931147635377706 Open DOISearch in Google Scholar

18 S. Tamaki, T. Yamada, T. Watanabe, T. Morita, Y. Furukawa, M. Kawasaki, A. Kikuchi, T. Kawai, M. Seo, M. Abe, J. Nakamura, K. Yamamoto, K. Kayama, M. Kawahira, K. Tanabe, K. Fujikawa, M. Hata, Y. Fujita, Y. Umayahara, S. Taniuchi, S. Sanada, A. Shintani, M. Fukunami, “Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study”, Circ Heart Fail, vol. 14 no. 3, March 2021. doi: 10.1161/CIRCHEARTFAILURE.120.007048. Erratum in: Circ Heart Fail, vol. 14 no. 4, April 2021. PMID: 33663235 TamakiS. YamadaT. WatanabeT. MoritaT. FurukawaY. KawasakiM. KikuchiA. KawaiT. SeoM. AbeM. NakamuraJ. YamamotoK. KayamaK. KawahiraM. TanabeK. FujikawaK. HataM. FujitaY. UmayaharaY. TaniuchiS. SanadaS. ShintaniA. FukunamiM. “Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study” Circ Heart Fail 14 3 March 2021 10.1161/CIRCHEARTFAILURE.120.007048 Erratum in: Circ Heart Fail, vol. 14 no. 4, April 2021. PMID: 33663235 33663235 Open DOISearch in Google Scholar

19 E.M. Boorsma, J.C. Beusekamp, J.M. Ter Maaten, S.M. Figarska, A.H.J. Danser, D.J. van Veldhuisen, P. van der Meer, H.J.L. Heerspink, K. Damman, A.A. Voors, “Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure”, Eur J Heart Fail, vol. 23 no. 1, pp. 68–78, Dec 2020. doi: 10.1002/ejhf.2066 PMID: 33251643 PMCID: PMC8048437 BoorsmaE.M. BeusekampJ.C. Ter MaatenJ.M. FigarskaS.M. DanserA.H.J. van VeldhuisenD.J. van der MeerP. HeerspinkH.J.L. DammanK. VoorsA.A. “Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure” Eur J Heart Fail 23 1 68 78 Dec 2020 10.1002/ejhf.2066 PMID: 33251643 PMCID: PMC8048437 804843733251643 Open DOISearch in Google Scholar

20 K. Damman, J.C. Beusekamp, E.M. Boorsma, H.P. Swart, T.D.J. Smilde, A. Elvan, J.W.M. van Eck, H.J.L. Heerspink, A.A. Voors, “Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)”, Eur J Heart Fail, vol. 22 no. 4, pp. 713–722, Jan 2020. doi: 10.1002/ejhf.1713 PMID: 31912605 DammanK. BeusekampJ.C. BoorsmaE.M. SwartH.P. SmildeT.D.J. ElvanA. van EckJ.W.M. HeerspinkH.J.L. VoorsA.A. “Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)” Eur J Heart Fail 22 4 713 722 Jan 2020 10.1002/ejhf.1713 PMID: 31912605 31912605 Open DOISearch in Google Scholar

21 K.M. Hallow, G. Helmlinger, P.J. Greasley, J.J.V. McMurray, D.W. Boulton, “Why do SGLT₂ inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis”, Diabetes Obes Metab, vol. 20 no. 3, pp. 479–487, Nov 2017. doi: 10.1111/dom.13126 PMID: 29024278 HallowK.M. HelmlingerG. GreasleyP.J. McMurrayJ.J.V. BoultonD.W. “Why do SGLT₂ inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis” Diabetes Obes Metab 20 3 479 487 Nov 2017 10.1111/dom.13126 PMID: 29024278 29024278 Open DOISearch in Google Scholar

22 K. Charaya, D. Shchekochikhin, D. Andreev, I. Dyachuk, S. Tarasenko, M. Poltavskaya, D. Mesitskaya, A. Bogdanova, N. Ananicheva, A. Kuzub, “Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study”, Open Heart, vol. 9 no. 1, May 2022. doi: 10.1136/openhrt-2021-001936 PMID: 35609943; PMCID: PMC9131063 CharayaK. ShchekochikhinD. AndreevD. DyachukI. TarasenkoS. PoltavskayaM. MesitskayaD. BogdanovaA. AnanichevaN. KuzubA. “Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study” Open Heart 9 1 May 2022 10.1136/openhrt-2021-001936 PMID: 35609943; PMCID: PMC9131063 913106335609943 Open DOISearch in Google Scholar

23 B.J. Kraus, M.R. Weir, G.L. Bakris, M. Mattheus, D.Z.I. Cherney, N. Sattar, H.J.L. Heerspink, I. Ritter, M. von Eynatten, B. Zinman, S.E. Inzucchi, C. Wanner, A. Koitka-Weber, “Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial”, Kidney Int, vol. 99 no. 3, pp. 750–762, Mar 2021. doi: 10.1016/j.kint.2020.10.031 PMID: 33181154 KrausB.J. WeirM.R. BakrisG.L. MattheusM. CherneyD.Z.I. SattarN. HeerspinkH.J.L. RitterI. von EynattenM. ZinmanB. InzucchiS.E. WannerC. Koitka-WeberA. “Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial” Kidney Int 99 3 750 762 Mar 2021 10.1016/j.kint.2020.10.031 PMID: 33181154 33181154 Open DOISearch in Google Scholar

24 L.M. Pérez-Belmonte, M. Ricci, J. Sanz-Cánovas, M. Millán-Gómez, J. Osuna-Sánchez, M.I. Ruiz-Moreno, M.R. Bernal-López, M.D. López-Carmona, M. Jiménez-Navarro, J.J. Gómez-Doblas, J.P. Lara, R. Gómez-Huelgas, “Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure”, J Clin Med, vol. 10 no. 16, p. 3540, August 2021. doi: 10.3390/jcm10163540 PMID: 34441835 PMCID: PMC8396978 Pérez-BelmonteL.M. RicciM. Sanz-CánovasJ. Millán-GómezM. Osuna-SánchezJ. Ruiz-MorenoM.I. Bernal-LópezM.R. López-CarmonaM.D. Jiménez-NavarroM. Gómez-DoblasJ.J. LaraJ.P. Gómez-HuelgasR. “Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure” J Clin Med 10 16 3540 August 2021 10.3390/jcm10163540 PMID: 34441835 PMCID: PMC8396978 839697834441835 Open DOISearch in Google Scholar

25 R.H.M. Furtado, I. Raz, E.L. Goodrich, S.A. Murphy, D.L. Bhatt, L.A. Leiter, D.K. McGuire, J.P.H. Wilding, P. Aylward, A.J. Dalby, M. Dellborg, D. Dimulescu, J.C. Nicolau, A.J.M. Oude Ophuis, A. Cahn, O. Mosenzon, I. Gause-Nilsson, A.M. Langkilde, M.S. Sabatine, S.D. Wiviott, “Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial”, vol. 145 no. 21, pp. 1581–1591, May 2022. doi: 10.1161/CIRCULATIONAHA.121.058103 PMID: 35510542. FurtadoR.H.M. RazI. GoodrichE.L. MurphyS.A. BhattD.L. LeiterL.A. McGuireD.K. WildingJ.P.H. AylwardP. DalbyA.J. DellborgM. DimulescuD. NicolauJ.C. Oude OphuisA.J.M. CahnA. MosenzonO. Gause-NilssonI. LangkildeA.M. SabatineM.S. WiviottS.D. “Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial” 145 21 1581 1591 May 2022 10.1161/CIRCULATIONAHA.121.058103 PMID: 35510542. 35510542 Open DOISearch in Google Scholar

26 Kosiborod et al., “Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial”, Lancet Diabetes Endocrinol, vol. 9, pp. 586–94, 2021. Kosiborod “Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial” Lancet Diabetes Endocrinol 9 586 94 2021 10.1016/S2213-8587(21)00180-7829480734302745 Search in Google Scholar

27 Z.L. Cox, S.P. Collins, M. Aaron, G.A. Hernandez, A.T.M. Iii, B.T. Davidson, M. Fowler, C.J. Lindsell, F.E.H. Jr, C.A. Jenkins, C. Kampe, K.F. Miller, W.B. Stubblefield, J. Lindenfeld, “Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial”, Am Heart J, 232, pp. 116–124, Feb 2021. doi: 10.1016/j.ahj.2020.10.071 PMID: 33144086 CoxZ.L. CollinsS.P. AaronM. HernandezG.A. IiiA.T.M. DavidsonB.T. FowlerM. LindsellC.J. JrF.E.H. JenkinsC.A. KampeC. MillerK.F. StubblefieldW.B. LindenfeldJ. “Efficacy and safety of dapagliflozin in acute heart failure: Rationale and design of the DICTATE-AHF trial” Am Heart J 232 116 124 Feb 2021 10.1016/j.ahj.2020.10.071 PMID: 33144086 33144086 Open DOISearch in Google Scholar

28 D. von Lewinski, M. Benedikt, N. Tripolt, M. Wallner, H. Sourij, E. Kolesnik, “Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?”, Kardiol Pol, vol. 79 no. 5, pp.503–509, 2021. doi: 10.33963/KP.15969 PMID: 34125922 von LewinskiD. BenediktM. TripoltN. WallnerM. SourijH. KolesnikE. “Can sodium-glucose cotransporter 2 inhibitors be beneficial in patients with acute myocardial infarction?” Kardiol Pol 79 5 503 509 2021 10.33963/KP.15969 PMID: 34125922 34125922 Open DOISearch in Google Scholar

29 L. Cavka, U. Bencak Ferko, N. Pitz, Z. Trpkovski, M. Lainscak, “Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction”, ESC Heart Fail, vol. 8 no. 4, pp. 2631–2636, August 2021. doi: 10.1002/ehf2.13452 PMID: 34102028 PMCID: PMC8318418 CavkaL. Bencak FerkoU. PitzN. TrpkovskiZ. LainscakM. “Sodium-glucose cotransporter 2 inhibitor-induced euglycaemic diabetic ketoacidosis in heart failure with preserved ejection fraction” ESC Heart Fail 8 4 2631 2636 August 2021 10.1002/ehf2.13452 PMID: 34102028 PMCID: PMC8318418 831841834102028 Open DOISearch in Google Scholar

30 R. Wachter, M. Senni, J. Belohlavek, E. Straburzynska-Migaj, K.K. Witte, Z. Kobalava, C. Fonseca, E. Goncalvesova, Y. Cavusoglu, A. Fernandez, S. Chaaban, E. Bøhmer, A.C. Pouleur, C. Mueller, C. Tribouilloy, E. Lonn, J. A.L. Buraiki, J. Gniot, M. Mozheiko, M. Lelonek, A. Noè, H. Schwende, W. Bao, D. Butylin, D. Pascual-Figal, “TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study”, Eur J Heart Fail., vol. 21 no. 8, pp. 998–1007, August 2019. doi: 10.1002/ejhf.1498 PMID: 31134724 WachterR. SenniM. BelohlavekJ. Straburzynska-MigajE. WitteK.K. KobalavaZ. FonsecaC. GoncalvesovaE. CavusogluY. FernandezA. ChaabanS. BøhmerE. PouleurA.C. MuellerC. TribouilloyC. LonnE. BuraikiJ. A.L. GniotJ. MozheikoM. LelonekM. NoèA. SchwendeH. BaoW. ButylinD. Pascual-FigalD. “TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study” Eur J Heart Fail. 21 8 998 1007 August 2019 10.1002/ejhf.1498 PMID: 31134724 31134724 Open DOISearch in Google Scholar

31 E.J. Velazquez, D.A. Morrow, A.D. DeVore, C.I. Duffy, A.P. Ambrosy, K. McCague, R. Rocha, E. Braunwald, “PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure”, N Engl J Med, vol. 380 no. 6, pp. 539–548, Feb 2019. doi: 10.1056/NEJMoa1812851 Erratum in: N Engl J Med. vol. 380 no. 11, p. 1090, March 2019. PMID: 30415601 VelazquezE.J. MorrowD.A. DeVoreA.D. DuffyC.I. AmbrosyA.P. McCagueK. RochaR. BraunwaldE. “PIONEER-HF Investigators. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure” N Engl J Med 380 6 539 548 Feb 2019 10.1056/NEJMoa1812851 Erratum in: N Engl J Med. vol. 380 no. 11, p. 1090, March 2019. PMID: 30415601 30415601 Open DOISearch in Google Scholar

32 D.Y. Chen, C.C. Chen, C.N. Tseng, S.W. Chen, S.H. Chang, W.K. Huang, M.S. Wen, M.J. Hsieh, I.C. Hsieh, “Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study”, EClinicalMedicine, 8;41:101149, Oct 2021. doi: 10.1016/j.eclinm.2021.101149 PMID: 34693232 PMCID: PMC8515399 ChenD.Y. ChenC.C. TsengC.N. ChenS.W. ChangS.H. HuangW.K. WenM.S. HsiehM.J. HsiehI.C. “Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study” EClinicalMedicine 8 41 101149 Oct 2021 10.1016/j.eclinm.2021.101149 PMID: 34693232 PMCID: PMC8515399 851539934693232 Open DOISearch in Google Scholar

33 T. Martyn et al., “Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy”, J Card Fail, vol. 27 no. 3, pp. 368–372, March 2021. MartynT. “Acute Hemodynamic Effects of Sacubitril-Valsartan In Heart Failure Patients Receiving Intravenous Vasodilator and Inotropic Therapy” J Card Fail 27 3 368 372 March 2021 10.1016/j.cardfail.2020.12.01333358957 Search in Google Scholar

34 J.S. Tran, O. Havakuk, J.M. McLeod, J. Hwang, H.Y. Kwong, D. Shavelle, M.R. Zile, U. Elkayam, M.W. Fong, L.P. Grazette, “Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction”, ESC Heart Fail, vol. 8 no. 2, pp. 1706–1710, April 2021. doi: 10.1002/ehf2.13225 PMID: 33522140 PMCID: PMC8006690 TranJ.S. HavakukO. McLeodJ.M. HwangJ. KwongH.Y. ShavelleD. ZileM.R. ElkayamU. FongM.W. GrazetteL.P. “Acute pulmonary pressure change after transition to sacubitril/valsartan in patients with heart failure reduced ejection fraction” ESC Heart Fail 8 2 1706 1710 April 2021 10.1002/ehf2.13225 PMID: 33522140 PMCID: PMC8006690 800669033522140 Open DOISearch in Google Scholar

35 M.A. Pfeffer et al., “Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction”, N Engl J Med, 385, pp. 1845–1855, 2021. doi: 10.1056/NEJMoa2104508 PfefferM.A. “Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction” N Engl J Med 385 1845 1855 2021 10.1056/NEJMoa2104508 34758252 Open DOISearch in Google Scholar

36 D. Carballo, J. Stirnemann, N. Garin, C. Marti, J. Serratrice, S. Carballo, “Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure”, ESC Heart Fail, vol. 7 no. 3, pp. 1282–1290, March 2020. doi: 10.1002/ehf2.12676 PMID: 32167679 PMCID: PMC7261587 CarballoD. StirnemannJ. GarinN. MartiC. SerratriceJ. CarballoS. “Eligibility for sacubitril-valsartan in patients with acute decompensated heart failure” ESC Heart Fail 7 3 1282 1290 March 2020 10.1002/ehf2.12676 PMID: 32167679 PMCID: PMC7261587 726158732167679 Open DOISearch in Google Scholar

37 S. Carballo, J. Stirnemann, N. Garin, P. Darbellay Farhoumand, J. Serratrice, D. Carballo, “Prognosis of patients eligible for dapagliflozin in acute heart failure”, Eur J Clin Invest, vol. 50 no. 6, June 2020. doi: 10.1111/eci.13245 PMID: 32306388 CarballoS. StirnemannJ. GarinN. Darbellay FarhoumandP. SerratriceJ. CarballoD. “Prognosis of patients eligible for dapagliflozin in acute heart failure” Eur J Clin Invest 50 6 June 2020 10.1111/eci.13245 PMID: 32306388 32306388 Open DOISearch in Google Scholar

38 M. Fudim, S. Sayeed, H. Xu, R.A. Matsouaka, P.A. Heidenreich, E.J. Velazquez, C.W. Yancy, G.C. Fonarow, A.F. Hernandez, A.D. DeVore, “Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction”, Circ Heart Fail., vol. 13 no. 4, April 2020. doi: 10.1161/CIRCHEARTFAILURE.119.006645 PMID: 32248695 PMCID: PMC8819257 FudimM. SayeedS. XuH. MatsouakaR.A. HeidenreichP.A. VelazquezE.J. YancyC.W. FonarowG.C. HernandezA.F. DeVoreA.D. “Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction” Circ Heart Fail. 13 4 April 2020 10.1161/CIRCHEARTFAILURE.119.006645 PMID: 32248695 PMCID: PMC8819257 881925732248695 Open DOISearch in Google Scholar

39 H. Kurdi, P. Shah, S. Barker, D. Harris, B. Dicken, C. Edwards, G. Jenkins, “Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure”, Br J Cardiol, vol. 28 no. 2, April 2021. doi: 10.5837/bjc.2021.018 PMID: 35747454 PMCID: PMC8822528 KurdiH. ShahP. BarkerS. HarrisD. DickenB. EdwardsC. JenkinsG. “Eligibility for dapagliflozin in unselected patients hospitalised with decompensated heart failure” Br J Cardiol 28 2 April 2021 10.5837/bjc.2021.018 PMID: 35747454 PMCID: PMC8822528 882252835747454 Open DOISearch in Google Scholar

40 N.S. Bassi, B. Ziaeian, C.W. Yancy, G.C. Fonarow, “Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure. JAMA Cardiol”, vol. 5 no. 8, pp. 948–951, Aug 2020. doi: 10.1001/jamacardio.2020.0898 PMID: 32374344 PMCID: PMC7203666 BassiN.S. ZiaeianB. YancyC.W. FonarowG.C. Association of Optimal Implementation of Sodium-Glucose Cotransporter 2 Inhibitor Therapy With Outcome for Patients With Heart Failure JAMA Cardiol 5 8 948 951 Aug 2020 10.1001/jamacardio.2020.0898 PMID: 32374344 PMCID: PMC7203666 720366632374344 Open DOISearch in Google Scholar

41 A. Ntalianis, C. Chrysohoou, G. Giannakoulas, G. Giamouzis, A. Karavidas, A. Naka, C.H. Papadopoulos, S. Patsilinakos, J. Parissis, D. Tziakas, J. Kanakakis, “Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper”, Heart Fail Rev, vol. 27 no. 1, pp. 1–13, May 2021. doi: 10.1007/s10741-021-10115-8 PMID: 33931815 PMCID: PMC8087533 NtalianisA. ChrysohoouC. GiannakoulasG. GiamouzisG. KaravidasA. NakaA. PapadopoulosC.H. PatsilinakosS. ParissisJ. TziakasD. KanakakisJ. “Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper” Heart Fail Rev 27 1 1 13 May 2021 10.1007/s10741-021-10115-8 PMID: 33931815 PMCID: PMC8087533 808753333931815 Open DOISearch in Google Scholar

42 D. Tomasoni, G.C. Fonarow, M. Adamo, S.D. Anker, J. Butler, A.J.S. Coats, G. Filippatos, S.J. Greene, T.A. McDonagh, P. Ponikowski, G. Rosano, P. Seferovic, M. Vaduganathan, A.A. Voors, M. Metra, “Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction”, Eur J Heart Fail, vol. 24, no. 3, pp. 431–441, March 2022. doi: 10.1002/ejhf.2397 PMID: 34894038; PMCID: PMC9303969 TomasoniD. FonarowG.C. AdamoM. AnkerS.D. ButlerJ. CoatsA.J.S. FilippatosG. GreeneS.J. McDonaghT.A. PonikowskiP. RosanoG. SeferovicP. VaduganathanM. VoorsA.A. MetraM. “Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction” Eur J Heart Fail 24, 3 431 441 March 2022 10.1002/ejhf.2397 PMID: 34894038; PMCID: PMC9303969 930396934894038 Open DOISearch in Google Scholar

43 A. Tymińska, K. Ozierański, M. Grabowski, G. Opolski, P. Balsam, “Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure”, Cardiol J, vol. 27 no. 5, pp. 625–632, 2020. doi: 10.5603/CJ.a2020.0094 PMID: 32648251 PMCID: PMC8078992 TymińskaA. OzierańskiK. GrabowskiM. OpolskiG. BalsamP. “Feasibility of sacubitril/valsartan initiation early after acute decompensated heart failure” Cardiol J 27 5 625 632 2020 10.5603/CJ.a2020.0094 PMID: 32648251 PMCID: PMC8078992 807899232648251 Open DOISearch in Google Scholar

44 E. Gayat, M. Arrigo, S. Littnerova, N. Sato, J. Parenica, S. Ishihara, J. Spinar, C. Muller, V.P. Harjola, J. Lassus, O. Miro, A.P. Maggioni, K.F. AlHabib, D.J. Choi, J.J. Park, Y. Zhang, J. Zhang, J.L. Januzzi, K. Kajimoto Jr., A. Cohen-Solal, A. Mebazaa, G. Network, “Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study”, Eur J Heart Fail 20:345354, 2018. GayatE. ArrigoM. LittnerovaS. SatoN. ParenicaJ. IshiharaS. SpinarJ. MullerC. HarjolaV.P. LassusJ. MiroO. MaggioniA.P. AlHabibK.F. ChoiD.J. ParkJ.J. ZhangY. ZhangJ. JanuzziJ.L. KajimotoK.Jr. Cohen-SolalA. MebazaaA. NetworkG. “Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study” Eur J Heart Fail 20 345354 2018 10.1002/ejhf.93228849606 Search in Google Scholar

45 J.J.V. McMurray, S.D. Solomon, S.E. Inzucchi, L. Køber, M.N. Kosiborod, F.A. Martinez, P. Ponikowski, M.S. Sabatine, I.S. Anand, J. Belohlavek, M. Böhm, C-E Chiang, V.K. Chopra, R.A. de Boer, A.S. Desai, M. Diez, J. Drozdz, A. Dukat, J. Ge, J.G. Howlett, T. Katova, M. Kitakaze, C.E.A. Ljungman, B. Merkely, J.C. Nicolau, E. O’Meara, M.C. Petrie, P.N. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D.L. DeMets, K.F. Docherty, P.D. Jhund, O. Bengtsson, M. Sjöstrand, A.M. Langkilde, DAPA-HF Trial Committees and Investigators, “Dapagliflozin in patients with heart failure and reduced ejection fraction”, N Engl J Med, 2019. 381:19952008. McMurrayJ.J.V. SolomonS.D. InzucchiS.E. KøberL. KosiborodM.N. MartinezF.A. PonikowskiP. SabatineM.S. AnandI.S. BelohlavekJ. BöhmM. ChiangC-E ChopraV.K. de BoerR.A. DesaiA.S. DiezM. DrozdzJ. DukatA. GeJ. HowlettJ.G. KatovaT. KitakazeM. LjungmanC.E.A. MerkelyB. NicolauJ.C. O’MearaE. PetrieM.C. VinhP.N. SchouM. TereshchenkoS. VermaS. HeldC. DeMetsD.L. DochertyK.F. JhundP.D. BengtssonO. SjöstrandM. LangkildeA.M. DAPA-HF Trial Committees and Investigators “Dapagliflozin in patients with heart failure and reduced ejection fraction” N Engl J Med 2019 381 19952008 10.1056/NEJMoa191130331535829 Search in Google Scholar

46 S. Yusuf, M.A. Pfeffer, K. Swedberg, C.B. Granger, P. Held, J.J. McMurray, E.L. Michelson, B. Olofsson, J. Ostergren, CHARM Investigators and Committees, “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial”, Lancet, 2003. 362:777781 YusufS. PfefferM.A. SwedbergK. GrangerC.B. HeldP. McMurrayJ.J. MichelsonE.L. OlofssonB. OstergrenJ. CHARM Investigators and Committees “Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial” Lancet 2003 362 777781 10.1016/S0140-6736(03)14285-713678871 Search in Google Scholar

47 B. Pitt, M.A. Pfeffer, S.F. Assmann, R. Boineau, I.S. Anand, B. Claggett, N. Clausell, A.S. Desai, R. Diaz, J.L. Fleg, I. Gordeev, B. Harty, J.F. Heitner, C.T. Kenwood, E.F. Lewis, E. O’Meara, J.L. Probstfield, T. Shaburishvili, S.J. Shah, S.D. Solomon, N.K. Sweitzer, S. Yang, S.M. McKinlay, TOPCAT Investigators, “Spironolactone for heart failure with preserved ejection fraction”, N Engl J Med, 2014. 370:13831392. PittB. PfefferM.A. AssmannS.F. BoineauR. AnandI.S. ClaggettB. ClausellN. DesaiA.S. DiazR. FlegJ.L. GordeevI. HartyB. HeitnerJ.F. KenwoodC.T. LewisE.F. O’MearaE. ProbstfieldJ.L. ShaburishviliT. ShahS.J. SolomonS.D. SweitzerN.K. YangS. McKinlayS.M. TOPCAT Investigators “Spironolactone for heart failure with preserved ejection fraction” N Engl J Med 2014 370 13831392 10.1056/NEJMoa131373124716680 Search in Google Scholar

48 S.D. Solomon, J.J.V. McMurray, I.S. Anand, J. Ge, C.S.P. Lam, A.P. Maggioni, F. Martinez, M. Packer, M.A. Pfeffer, B. Pieske, M.M. Redfield, J.L. Rouleau, D.J. van Veldhuisen, F. Zannad, M.R. Zile, A.S. Desai, B. Claggett, P.S. Jhund, S.A. Boytsov, J. Comin-Colet, J. Cleland, H.D. Dungen, E. Goncalvesova, T. Katova, J.F. Kerr Saraiva, M. Lelonek, B. Merkely, M. Senni, S.J. Shah, J. Zhou, A.R. Rizkala, J. Gong, V.C. Shi, M.P. Lefkowitz, PARAGON-HF Investigators and Committees, “Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction”, N Engl J Med, 2019. 381:16091620 SolomonS.D. McMurrayJ.J.V. AnandI.S. GeJ. LamC.S.P. MaggioniA.P. MartinezF. PackerM. PfefferM.A. PieskeB. RedfieldM.M. RouleauJ.L. van VeldhuisenD.J. ZannadF. ZileM.R. DesaiA.S. ClaggettB. JhundP.S. BoytsovS.A. Comin-ColetJ. ClelandJ. DungenH.D. GoncalvesovaE. KatovaT. Kerr SaraivaJ.F. LelonekM. MerkelyB. SenniM. ShahS.J. ZhouJ. RizkalaA.R. GongJ. ShiV.C. LefkowitzM.P. PARAGON-HF Investigators and Committees “Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction” N Engl J Med 2019 381 16091620 10.1056/NEJMoa190865531475794 Search in Google Scholar